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Abstract
Background: Previous studies have shown a major green tea polyphenol (−)-epigallocatechin-3-gallate ((−)-EGCG)
as a powerful anti-cancer agent. However, its poor bioavailability and requirement of a high dosage to manifest
activity have restricted its clinical application. Recently, our team synthesized a peracetate-protected derivative of
EGCG, which can act as a prodrug of (−)-EGCG (ProEGCG) with enhanced stability and improved bioavailability
in vitro and in vivo. Herein, we tested the therapeutic efficacy of this novel ProEGCG, in comparison to EGCG,
toward human endometrial cancer (EC).
Methods: In this study, the effects of ProEGCG and EGCG treatments on cell growth, cell survival and modulation
of intracellular signaling pathways in RL95–2 and AN3 CA EC cells were compared. The antiproliferative effect was
evaluated by cell viability assay. Apoptosis was measured by annexin/propidium iodide staining. Expression of
mitogen-activated protein kinases, markers of proliferation and apoptosis were measured by immunoblot analysis.
In addition, the effects of ProEGCG and EGCG on tumor growth, vessel formation and gene expression profiles on
xenograft models of the EC cells were investigated.
Results: We found that treatment with ProEGCG, but not EGCG, inhibited, in a time- and dose-dependent manner,
the proliferation and increased apoptosis of EC cells. Treatment with low-dose ProEGCG significantly enhanced
phosphorylation of JNK and p38 MAPK and inhibited phosphorylation of Akt and ERK which are critical mediators
of apoptosis. ProEGCG, but not EGCG, elicited a significant decrease in the growth of the EC xenografts, promoted
apoptotic activity of tumour cells in the EC xenografts, and decreased microvessel formation, by differentially
suppressing anti-apoptotic molecules, NOD1 and NAIP. Notably, no obvious adverse effects were detected.
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Conclusions: Taken together, ProEGCG at a low dose exhibited anticancer activity in EC cells through its anti-
proliferative, pro-apoptotic and anti-tumor actions on endometrial cancer in vitro and in vivo. In contrast, a low
dose of EGCG did not bring about similar effects. Importantly, our data demonstrated the efficacy and safety of
ProEGCG which manifests the potential of a novel anticancer agent for the management of endometrial cancer.
Keywords: ProEGCG, Endometrial cancer, Apoptosis, Anticancer, Anti-angiogenesis, Akt pathway
Background
Endometrial cancer (EC) is one of the most common
gynecological malignancies in the developed world. It
ranked as the sixth most common cause of death from
cancer which only affects women, and the 15th most
commonly occurring cancer overall [1]. Although the
majority of ECs are diagnosed and can be treated when
confined to the uterus, recurrence has been reported in
up to 25% of the cases. The response rate of advanced
and metastatic cancer to standard chemotherapy is typ-
ically low, and consequently patient prognosis remains
poor. Given the escalating incidence of this cancer and
the paucity of effective treatments for advanced EC, it is
imperative to search for novel agents for the effective
management of this cancer.
Tea is the second most popular beverage in the world
after water. The polyphenol found in green tea, (−)-epi-
gallocatechin-3-gallate (EGCG), exhibits potent anti-
oxidative, anti-mitotic and anti-angiogenic properties
[2–4]. EGCG has long been known to inhibit carcino-
genesis of diverse tumor types [5–7]. It acts through
inhibiting a variety of cancer-related pathways, including
cell proliferation and tumor growth, invasion and
metastasis, and angiogenesis, and to induce apoptosis
and cell cycle arrest in transformed cells. EGCG is de-
void of significant untoward side-effects and toxicity,
and thus has gained considerable attraction as a poten-
tial therapeutic in clinical scenarios. However, the bulk
of these studies employed an exceedingly high dosage
which is pharmacologically infeasible [3, 8, 9]. In
addition, EGCG is notoriously unstable and has the
shortcoming of poor bioavailability [10]. Hence, in re-
cent years, our team synthesized a peracetate-protected
derivative of EGCG, produced by acetylation of EGCG,
which can act as a prodrug of EGCG (ProEGCG) with
enhanced stability and improved bioavailability in vitro
and in vivo [11] (Fig. 1).
The effectiveness of ProEGCG on breast cancer cells
and in breast cancer–bearing nude mice was proven by
the elevated levels of proteasome inhibition, growth sup-
pression, and induction of apoptosis [12–14]. In
addition, ProEGCG with anti-oxidative and anti-
angiogenic activities significantly thwarted the develop-
ment, growth and angiogenesis of experimental endo-
metriosis in mice with high efficacy and good
bioavailability [15]. Recently, we demonstrated that
Fig. 1 Molecular structures of EGCG (a) and ProEGCG (b)
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ProEGCG not only downregulated vascular endothelial
growth factors (VEGFs) but also inhibited tumor-
associated macrophage (TAM)-secreted VEGFA in EC
[16].
Despite the efficacy of ProEGCG in suppressing cancer
growth, its therapeutic effect and underlying mechanism
on EC cells remain to be elucidated. Hence, in this
study, we investigated the anticancer effect and the re-
lated mechanisms of ProEGCG toward EC cells. Add-
itionally, in order to acquire more knowledge necessary
for the design of drugs for preclinical usage, we explored
the in vivo therapeutic effect of ProEGCG by using two
subcutaneous xenograft models of endometrial cancer.
Methods
Reagents and chemicals
HPLC-grade (−)-Epigallocatechin-3-gallate (EGCG, 99%
purity), dimethyl sulfoxide (DMSO), and (3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT)
were purchased from Sigma-Aldrich. Dulbecco’s modi-
fied Eagle’s Medium, α-modified Eagle’s Medium and
0.5% trypsin-5.3 mm EDTA solution, certified fetal bo-
vine serum (FBS)-heat inactivated and penicillin–
streptomycin–neomycin antibiotic mixture was obtained
from Thermo Fisher Scientific (Burlington, Canada).
Amersham ECL Western blotting detection reagents
were purchased from GE Healthcare Biosciences (Pitts-
burgh, PA).
ProEGCG synthesis
ProEGCG (EGCG octaacetate) (purity ≥98%) was syn-
thesized from (−)-EGCG by acetylation of the reactive
hydroxyl groups according to our published procedure
[11]. Purity was determined by by liquid chromatog-
raphy. For all experiments, EGCG and ProEGCG were
always freshly prepared in a DMSO stock solution
(1000×) and the solution was directly diluted to a de-
sired concentration with the culture medium so that the
final concentration of DMSO did not exceed 0.1%.
Cell lines
Two human EC cell lines, AN3 CA (Cat. No. ATCC®
HTB111) and RL95–2 (Cat. No. ATCC® CRL-1671) were
purchased from American Type Culture Collection
(ATCC) while a normal human endometrial epithelial
cell (HEECs) cell line was bought from Wuhan PriCells
Biomedical Technology (China). AN3CA cells were
grown in α-EMEM supplemented with 10% FBS and 1%
PSN, while RL95–2 and HEECs were cultured in
DMEM/F12 supplemented with 10% FBS and 1% PSN,
in an atmosphere of 5% CO2 at 37 °C.
Cell proliferation assay
Cell proliferation was measured using the 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) (Sigma-
Aldrich) dye reduction method. In brief, the cells were
plated at a density of 10,000 cells/well in a 96-well plate
and cultured in the respective culture medium. After in-
cubation for 24 h, the cells were treated with various
(20 μM – 60 μM concentrations) of either EGCG or
ProEGCG. Cells treated with 0.1% DMSO were used as
control. The medium was renewed daily. Cell viability
was determined at 24, 48, and 72 h by monitoring the
changes of absorbance using a microplate reader (Spec-
tramax, Gemini) at the wavelength of 570 nm. The per-
centage of survival cells was calculated as the ratio
(A570) of the absorbance of treated cells over the absorb-
ance of control cells. In each of the experiments, tripli-
cates were set up for each drug concentration (n = 5),
and assays were repeated in three independent
experiments.
3D culture
EC cells (AN3CA: 10,000 cells. RL95–2: 20,000 cells)
were mixed with 500 μl extracellular matrix (ECM;
Matrigel, BD Biosciences) and loaded into each well of
the chamber slide (Nunc Lab-Tek, Rochester, NY, USA).
After the gel had solidified, EC cells were seeded on top
of the gel, and treated with serial concentrations of ei-
ther EGCG (20, 40, and 60 μM) or ProEGCG (20, 40,
and 60 μM) for 5 days. In order to test the capability of
ProEGCG to reduce cell growth, the 3D monocultures
were allowed to form till day 7, prior to administering
either EGCG treatment or ProEGCG treatment for 5
days.
Flow cytometric detection of apoptosis
In the apoptosis assay, tumour cells (2 × 105 cells/ml)
were seeded in 6-well plates, and then treated with ei-
ther EGCG or ProEGCG for 48 h and 72 h. To analyze
apoptotic activity, floating and attached cells were col-
lected and analysed by double staining with FITC-
conjugated Annexin V and propidium iodide (PI) ac-
cording to the manufacturer’s instructions (Annexin V-
FITC Apoptosis Staining / Detection Kit, Abcam). The
percentage of apoptotic cells was analysed using a
Cytomics FC500 flow cytometer (Beckman Coulter) and
Cell-Quest software. For each sample, data from 10,000
cells were recorded.
Western blot analysis
Western blotting analysis was performed according to
our previous protocol [16]. In brief, the tumour cells
were grown to ~ 80% confluency in 100- mm dishes, and
then treated with either EGCG or ProEGCG for 72 h at
20, 40, and 60 μM concentration, with daily renewal of
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medium with EGCG (or ProEGCG). The treated and con-
trol cells were rinsed with PBS and harvested using lysis
buffer (50mM Tris–HCl, 150mM NaCl, 1% Nonidet,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate,
and 1 μM sodium orthovanadate) supplemented with pro-
tease inhibitor cocktail (Sigma-Aldrich). Protein concen-
trations were quantified using the Bio-Rad protein assay
kit. Equivalent amounts of total protein (30 μg) were sepa-
rated by employing 8 ~ 15% SDS–polyacrylamide gel elec-
trophoresis, transferred to a polyvinylidene difluoride
membrane, and subjected to Western blot analysis for
probing with primary antibodies (Akt1/2/3 (H-136), p-
Akt1/2/3 (Ser-473), ERK1 (K-23), p-ERK (E-4), JNK (FL),
p-JNK (G-7), p38α (C-20), p-p38 (D-8); GAPDH (FL-335)
from Santa Cruz Biotechnology Inc.; cleaved caspase-3
(Asp175) and cleaved PARP (Asp214) antibodies from
Cell Signalling Technology; caspase-3 (E-87) and CD34
(EPR2999) were obtained from Abcam). Then, the mem-
brane was incubated with appropriate horseradish perox-
idase conjugated secondary antibody and visualized with
the Amersham ECL Western blotting detection kit (GE
Healthcare Biosciences). Experiments were repeated in
three independent experiments.
In vivo tumor xenografts
Fifteen female athymic nude mice (nu/nu) (5–6 weeks
old, 16-20 g) were obtained from the Laboratory Animal
Services Centre of the Chinese University of Hong Kong.
The animals were kept in wire cages in laminar air flow
cabinets at a temperature of 20–22 °C, a humidity of 30–
50%, and a 12-h/12-h light/dark cycle. Autoclaved chow
pellets and autoclaved tap water were provided ad libi-
tum. The animal colonies were maintained in a specific
pathogen-free environment with regular screenings for
detecting the presence of murine pathogens. The experi-
mental protocol was conducted under the license from
the Hong Kong Department of Health and with approval
from the Chinese University of Hong Kong Animal Re-
search Ethics Committee. Endometrial xenografts were
established by implanting suspensions of endometrial
tumor cells, as previously described [16]. In brief, mice
were anesthetized in a chamber prefilled with 1.5% iso-
flurane in oxygen. Endometrial xenografts were then
established by implanting suspensions of endometrial
tumour cells (1 × 106 cells resuspended in 50 uL of
HBSS-buffer mixed with 50/50 (v/v) with Matrigel (BD
Biosciences, San Jose, CA)) subcutaneously into the right
flanks of the mice. Tumor growth was monitored
weekly, and tumor volumes (mm3) were measured with
an electronic caliper, using the following formula: tumor
volume (mm3) = 0.5 x length (mm) x width2 (mm2).
After 2 weeks, when the size of the tumor lesion reached
100 mm3, the mice were randomized into four groups
with the first group without treatment, and the
remaining three groups treated by oral gavage daily with
(group 2) ProEGCG (50 mg/kg), (group 3) EGCG (50
mg/kg) or (group 4) vehicle (olive oil) (n = 5 for each
group). Body weight and the tumours were regularly
monitored. At the end of the experiment, mice were
sacrificed by using an overdose of non-painful anaesthe-
sia (Ketamine/Xylazine cocktail). Macroscopic lesions
were recorded and metastatic tumor nodules were dis-
sected, weighed and paraffin-embedded for further im-
munohistochemical staining. In addition, blood was
taken for biochemical analyses (creatinine, alanine trans-
aminase (ALT) and alkaline phosphatase (ALP); Abcam).
Based on our previous publication, plasma levels of
ProEGCG can be maintained at 1.36 μg/mL for 360 min
after an intraorbital intravenous injection at 50 mg/kg in
mice [17]. In addition, the dosage was determined ac-
cording to our previous publication [16].
Apoptosis microarray
Total RNA in the endometrial tumour xenograft samples
was extracted by using RNeasy mini Plus kit (Qiagen). To
ascertain the apoptosis-related molecules regulated by
ProEGCG treatment, gene expression of the xenograft tis-
sues was examined by angiogenesis microarray. A micro-
array experiment was performed following previous
procedures [18]. Data were acquired by Feature Extraction
10.5 and analysed by GeneSpring GX software (Agilent).
Likewise, the microarray findings were further validated
by using quantitative real-time RT-PCR, based on previ-
ous experiments [18]. TaqMan probes of human NOD1
(Hs01036720_m1), NAIP (Hs03037952_m1), BAG1
(Hs00185390_m1) and GAPDH (Hs02758991_g1) were
used and purchased from Thermos Life Technologies.
Histological analysis
Tumour tissues were fixed in 10% buffered formalin
overnight and embedded in paraffin. The blocks were
cut into 4- μm micrometer thick slices for different
staining. Sections were stained with haemotoxylin and
eosin (HE) for morphological visualization. For immuno-
histochemistry, sections were incubated with the appro-
priate dilution of primary antibodies overnight, followed
by 3,3-diaminobenzidine (DAB) staining. Terminal deox-
ynucleotidyl transferase-mediated dUTP nick end label-
ling (TUNEL) staining was performed using the
ApopTag® peroxidase in situ apoptosis detection kit
(Milipore) according to the manufacturer’s instructions.
After mounting, images were captured with a Leica
DM2500 microscope for further processing using ImageJ
(Bethesda). Slides of endometrial cancer tissue samples
from the vehicle-treated xenograft were collected and in-
cubated with a brief treatment of DNAse 1 after
permeabilization were used as the positive control of the
TUNEL assay. Slides treated with isotype-matched IgG
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but without each primary antibody served as the nega-
tive control.
Statistical analysis
Statistical analysis was performed using the SPSS statis-
tics software (IBM Corp.). All results are presented as
mean ± standard error of the mean (S.E.M) from at least
three independent experiments. Student’s t-tests were
performed to analyse the differences between two
groups. One-way analysis of variance (ANOVA) followed
by post hoc comparisons of individual groups using Bon-
ferroni correction was used for comparisons between
multiple groups. In the event of an absence of normality
of distribution, nonparametric Kruskal-Wallis and Wil-
coxon tests were used where appropriate. Differences
were considered significant when P < 0.05.
Results
ProEGCG exerts an anti-proliferative effect in vitro on
human EC cell lines
The anti-proliferative effects of different concentrations
of ProEGCG and EGCG on two EC cell lines, RL95–2
and AN3 CA, were compared. ProEGCG lowered the
viability of the two EC cells in a dose- and time-
dependent manner (Fig. 2). In both RL95–2 and AN3
CA cells, ProEGCG significantly decreased cell prolifera-
tion at 40 μM and 60 μM concentrations after incubation
for 48 h (P < 0.05). Over 90% of both RL95–2 and AN3
CA endometrial cells became nonviable following expos-
ure to 60 μM ProEGCG for 72 h (P < 0.01). In contrast,
EGCG failed to elicit a significant reduction in the
growth of both EC cells (Fig. 2a and b). The IC50 value
of ProEGCG in RL95–2 cells was found to be 43.7 μM
and 38.0 μM after 48 h and 72 h (Fig. 2c), respectively,
whereas the IC50 value of ProEGCG in AN3 CA cells
was 48.8 μM and 34.7 μM after 48 h and 72 h (Fig.
2d), respectively. On the other hand, the profile of
cytotoxicity of ProEGCG to normal endometrial cells
(HEEC cells) revealed an IC50 value that exceeded
352 μM, suggesting that ProEGCG was nontoxic to
normal cells (Supplementary Fig. 1). In addition,
treatment with ProEGCG also significantly abolished
colony formation in the 3D monocultures of meta-
static EC cells when treated from day 2 to day 7
(Supplementary Fig. 2A) or when treated after 1 week
(Supplementary Fig. 2B).
Fig. 2 Effects of ProEGCG and EGCG on cell proliferation of human endometrial cancer cells. RL95–2 and AN3 CA cells were treated with
increasing doses of (a, b) EGCG (20, 40, and 60 μM) and (c, d) ProEGCG (20, 40, and 60 μM) for 24, 48 and 72 h. Cell viability was assessed by MTT
assay. The percentage of viable cells was calculated as the ratio of the number of treated cells to the number of control cells. Data are presented
as mean ± S.E.M. Significant differences from control: *P < 0.05 and **P < 0.01
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ProEGCG induces EC cell death via caspase dependent
apoptosis
The effects of ProEGCG and EGCG on the induction of
apoptosis in EC cells were assessed by FACS assay. A
significant induction of apoptosis was observed at all-
time intervals after treatment of both EC cell lines with
ProEGCG (Fig. 3a and b). However, EGCG did not bring
about any significant inhibition of the growth of endo-
metrial cells (Fig. 3a and b). This result was further veri-
fied by immunocytostaining of the EC cells with
Annexin V and PI after treatment with ProEGCG (Sup-
plementary Fig. 3). The data confirmed apoptotic activity
in the EC cells upon treatment with 40 and 60 μM
ProEGCG. Moreover, apoptosis was further detected in
both cell lines following treatment with ProEGCG and
EGCG by the presence of apoptotic markers, cleaved
caspase-3 and cleaved PARP, using Western blot ana-
lysis. ProEGCG upregulated the expression of cleaved
caspase-3 and cleaved PARP in a dose-dependent man-
ner (Fig. 3c). The apoptotic effect was found to be most
potent at 60 μM as more intense cleaved caspase-3 and
cleaved PARP bands were observed.
ProEGCG induces JNK and p38 MAPK phosphorylation
and suppresses Akt and ERK signaling in EC cells
To further investigate the anticancer mechanism of the
MAPK signaling pathway in EC cells by ProEGCG treat-
ment, in vitro cultures of human EC cells were per-
formed. The results showed that an increased
concentration of ProEGCG treatment significantly stim-
ulated the increased phosphorylation of JNK and p38
MAPK (Fig. 4). In contrast, a significant reduction of
phosphorylation of ERK in both EC cells after treatment
with ProEGCG for 72 h was observed (Fig. 4). The de-
cline in phosphorylation was most remarkable when EC
cells were treated with 60 μM ProEGCG. Likewise, there
was a similar reduction of phosphorylation of Akt in
both EC cells after 72 h of treatment with ProEGCG
(Fig. 4). However, these changes were not observed in
the EC cells treated with various concentrations of
EGCG.
ProEGCG reduces tumor growth in vivo
Subcutaneous tumor xenografts, developed from two
human EC cell lines (RL95–2 and AN3 CA), were suc-
cessfully established individually. ProEGCG elicited sig-
nificant growth inhibition of the lesion in the
endometrial tumor xenograft model. In the RL95–2
xenograft model, tumor size was significantly reduced
after 5 weeks of treatment with ProEGCG (Fig. 5a). The
tumor mass (g) was significantly reduced in mice treated
with ProEGCG (vehicle group: 0.55 ± 0.11 vs ProEGCG
group: 0.33 ± 0.16; P ≤ 0.05) (Fig. 5a). However, there
was no significant reduction in tumor mass in mice
treated with EGCG. In the AN3 CA xenograft model,
the tumour size was significantly reduced after oral ad-
ministration of ProEGCG for 3 weeks (Fig. 5b). This was
further confirmed by the reduction in tumour mass (g)
ex vivo (vehicle group: 1.45 ± 0.59 vs ProEGCG group:
0.60 ± 0.32; P ≤ 0.05) (Fig. 5b). Similarly, there was no
significant reduction found in mice treated with EGCG.
Notably, there was no toxicity found in both xenograft
models in response to treatment with ProEGCG (Fig.
5c).
Further analysis of the excised lesion disclosed induc-
tion of apoptosis and necrosis when the mice were
treated with ProEGCG (Fig. 6a and b). Similar to our
previous report, treatment with ProEGCG significantly
impeded angiogenesis qualitatively (Fig. 6a and b) as well
as quantitatively (Fig. 6c and d) in EC xenograft models.
The abated angiogenesis was further corroborated by the
significant diminution in microvessel density (Fig. 6c
and d). In addition, expression of genes associated with
apoptosis was also examined using microarray analysis
in the endometrial tumor xenograft tissues with or with-
out ProEGCG treatment. Our findings revealed signifi-
cant down-regulation of human NOD1, NAIP, and BIG1
in xenografts treated with ProEGCG compared to
vehicle-treated xenografts (Fig. 6e and f).
Discussion
In this study, we examined the growth inhibitory effect
of ProEGCG on EC cells both in vitro and in vivo. The
results indicated that ProEGCG decreased the viability
of human EC cells in a dose-dependent manner. In
addition, ProEGCG induced caspase-3 expression which
subsequently upregulated cleaved PARP and triggered
apoptosis. Treatment of EC cells with ProEGCG signifi-
cantly enhanced the phosphorylation of JNK and p38
MAPK and inhibited the phosphorylation of Akt and
ERK which are critical mediators of apoptosis. Consist-
ent with the in vitro findings, the therapeutic effects of
ProEGCG in the EC xenografts were revealed in a sig-
nificantly smaller tumour volume together with en-
hanced apoptotic activity and suppressed microvessel
formation.
Green tea is one of the most popular beverages con-
sumed around the world. Among the many polyphenolic
compounds, EGCG has been found to be the most ef-
fective chemopreventive agent. A sizeable number of
studies have shown that EGCG could suppress cell pro-
liferation and induce apoptosis in many types of cancer
cells [19–21]. However, EGCG has a low bioavailability
in vivo [10]. In order to uplift the stability of EGCG, we
synthesized a peracetate-protected EGCG (ProEGCG) by
modifying the reactive hydroxyl groups with peracetate
groups. The resulting ProEGCG was six fold more stable
than EGCG and it demonstrated an augmented efficacy
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Fig. 3 ProEGCG induced apoptosis in RL95–2 and AN3 CA cells in a time-dependent manner. Cells were treated with increasing concentrations
of EGCG and ProEGCG (a) RL95–2 cells and (b) AN3 CA cells for 48 h and (c) RL95–2 cells and (d) AN3 CA cells for 72 h. Apoptotic cells were
quantitatively analyzed by flow cytometry with annexin V-FITC and propidium iodide staining. e Lysates from cells treated with ProEGCG and
EGCG were assayed for PARP and caspase-3 cleavage by Western blotting. GAPDH was used as a loading control. Data are presented as mean ±
S.E.M. Significant differences from control: *P < 0.05 and **P < 0.01
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in inducing cancer cell death [11]. Likewise, the tumor
volume was significantly curtailed in xenograft models
of human breast cancer after administration of
ProEGCG [13]. More recently, we noted that ProEGCG
can exert an anti-angiogenic effect in human endomet-
rial cancer xenograft models through interference with
microvessel formation [16]. In this study, we further
demonstrated the anticancer effect of ProEGCG on
endometrial cancer cells in vitro and in vivo.
Apoptosis is a well-known cellular defence mechanism
that eliminates cancer cells and plays a vital role in the
prevention of tumorigenesis. Many anticancer drugs
work by regulating apoptosis-related signals to induce
cancer cell death [22, 23]. Although a study showed
EGCG can induce apoptosis in human endometrial
adenocarcinoma cells, it would require a relatively high
concentration of EGCG (100–150 uM) to significantly
reduce the cell viability and induce apoptosis [3]. In our
study, we utilized a lower concentration of EGCG (20–
60 uM) to find the lack of response on the EC cells. This
result actually resembled a previous finding [13]. In this
study, we investigated whether ProEGCG can induce
apoptosis in the human endometrial cancer cells.
Annexin V/FITC and PI were used to stain the cells in
order to distinguish between viable, apoptotic, and nec-
rotic cells [23]. Our experimental results showed that
apoptotic activity escalated with the concentration of
ProEGCG, while the percentages of early and late apop-
totic cells were also increased. While the process of
apoptosis in carcinoma involves a large number of
changes in the apoptotic proteins, our results showed
that ProEGCG markedly induced apoptosis of EC cells
by upregulation of the expression levels of cleaved
caspase-3 and cleaved PARP. However, these changes
were indiscernible when EC cells were treated with
EGCG.
Fig. 4 Effects of ProEGCG and EGCG on activating signaling Akt and MAPKs signaling pathway. Effects of ProEGCG and EGCG on the activation of
Akt, ERK, JNK and p-38 in human endometrial (a) RL95–2 cells and (b) AN3 CA cells by Western blotting. Representative Western blot of results
from 3 independent experiments are shown in upper panels. Quantification of protein expressions were measured. Full-length of the gels are
presented in Supplementary Fig. 5. Data are presented as mean ± S.E.M. Significant differences from control: *P < 0.05 and **P < 0.01
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The MAPKs is a family of serine/threonine kinases in-
volved in apoptosis and cell survival [24]. Based on the
findings of Mahoher et al., EGCG inhibits cellular prolif-
eration via inhibiting ERK activation and inducing apop-
tosis via ROS generation and p38 activation in
endometrial carcinoma cells [3]. Owing to ProEGCG be-
ing an analogue of EGCG, we analysed whether
ProEGCG has a role in affecting EC cell proliferation
through the expression of MAPKs p-38, JNK and ERK
in both EC cell lines. Our result showed an enhance-
ment in phosphorylation expression of JNK and p-38 in
both EC cell lines when treated with ProEGCG, which
implicated the induction of apoptosis by ProEGCG in
EC cells. Further, ERK activation was also downregu-
lated, which in turn might be responsible for the under-
mined cellular growth and proliferation of the EC cells.
With the MAPK pathway closely linked with the PI3K/
Akt pathway, a previous study showed the reduction of
cancer cells growth through inhibiting the PI3K/Akt/
mTOR signalling pathway [25]. The PI3K/Akt/mTOR
pathway is a key cellular signalling mechanism respon-
sible for proliferation, migration, metabolism, and drug
Fig. 5 ProEGCG inhibits proliferation of endometrial carcinoma in vivo. a Schematic establishment of the xenograft model in this study. b Rl95–2
and (c) AN3 CA cells were injected subcutaneously into athymic nude mice. Tumors were allowed to grow to a size around 100mm3 and were
then orally treated with ProEGCG (50 mg/kg), EGCG (50 mg/kg) or vehicle (olive oil) (n = 5 for each group). The increment of tumor volume and
changes of body weight were assessed longitudinally. d Evaluation of hemato-biochemical markers from plasma samples of tumor-bearing mice
after treatment with ProEGCG. Full-length of the gels are presented in Supplementary Fig. 5. Data are presented as mean ± S.E.M. Significant
differences from control: *P < 0.05 and **P < 0.01. ALP, alkaline phosphatase; ALT, alanine aminotransferase
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Fig. 6 Apoptotic and microvessel development in endometrial carcinoma xenograft tumors after ProEGCG treatment. Haemotoxylin & eosin
staining, TUNEL assay, caspase-3 and CD34 in (a) Rl95–2 and (b) AN3 CA xenograft tumors were analyzed by immunohistochemistry
(magnification 200x). c, d The expression levels of CD34-postive cells were quantified. e Hierarchical clustering shows differential regulation of
BAG1, NOD1 and NAIP (pink tree branch, yellow box) after EGCG and ProEGCG treatments in human EC cell xenografts. f Quantitative analysis by
real-time PCR validated the differential expression of NOD1, NAIP and BAG1 after EGCG and ProEGCG treatment in human EC cell lines. Data are
presented as mean ± S.E.M. Significant differences from control: *P < 0.05 and **P < 0.01
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resistance [26–29]. Similarly, the activation of Akt,
through a PI3K-dependent mechanism can also promote
apoptosis via signal-regulating kinase 1 (ASK1)/MAPK
signalling pathway [30]. According to our study, the
phosphorylation of Akt was attenuated by an increase in
the concentration of ProEGCG in the EC cells. Hence, a
possible mechanism of ProEGCG to trigger EC cell
death was to activate Akt, which further promotes sev-
eral proapoptotic signalling proteins in the MAPKs fam-
ilies, to stimulate apoptosis. Taken together, it is
suggested that ProEGCG induces rapid and transient ac-
tivation of Akt, which inhibits the PI3K/Akt/mTOR sig-
nalling pathway, and MAPK signalling pathway to
inhibit proliferation and promote apoptotic signal in the
EC cells.
Eventually, the activation of this signalling pathway
can trigger cell death by activating several proapoptotic
signalling proteins, including JNK and p38 MAPK. In
our study, the phosphorylation of Akt was attenuated by
an increase in the concentration of ProEGCG in the EC
cells. Hence, a possible mechanism of ProEGCG to trig-
ger EC cell death was to activate Akt, which further pro-
motes several proapoptotic signalling proteins in the
MAPKs families, to stimulate apoptosis. The PI3K/Akt/
mTOR pathway is a key signalling mechanism for cell
survival proliferation, migration, metabolism, and drug
resistance [26–29]. Taken together, the evidence suggest
that ProEGCG induces rapid and transient activation of
Akt, which in turn inhibits the PI3K/Akt/mTOR signal-
ling pathway, and MAPK signalling pathway to inhibit
proliferation and promote apoptotic signal in the EC
cells. The deregulation of the PI3K/Akt/mTOR pathway
plays a fundamental role in breast cancer, such that the
pharmacological suppression of PI3K/Akt/mTOR signal-
ling showed inhibition of tumor growth in vivo [31].
Also, our previous study demonstrated that treatment
with ProEGCG reduced tumour volume significantly in
xenograft models of human breast cancer through prote-
asome inhibition and apoptosis induction [13]. Hence, it
can be speculated that the ProEGCG would reduce
tumour growth through proteasome inhibition on p38
MAPK/ERK signalling regulation to enhance autophagy
and apoptosis.
By the same token, tumour growth was inhibited in
the EC xenograft models subsequent to administration
of ProEGCG. Based on the analysis of the lesion excised
after ProEGCG treatment, a higher expression of apop-
totic and necrotic activities was found (Fig. 6). Based on
our microarray analysis, we found suppression of anti-
apoptotic molecules, NOD1 and NAIP, in the cells
treated with ProEGCG. As previously reported, both
markers play central roles in anti-apoptotic activity and
repression of tumour growth by inhibiting multiple cas-
pase activities [32, 33]. And as reported in a previous
literature, NOD1 was found to have tumour suppressor
activity toward estrogen receptor (ER)-dependent breast
cancer in a xenograft model [34]. Likewise, in ER-
positive MCF-7 cells, NOD1 deficiency was found to be
correlated with tumour growth, an increased sensitivity
to estrogen-induced cell proliferation and impaired
Nod1-dependent apoptosis. Similarly, the Nod1-
dependent apoptosis was noted to be mediated by a cas-
pase 8-cascade in an RIP2-dependent manner [32]. In
another study, the proteomic profile of NOD-1 overex-
pressed cells suggests the involvement of several inflam-
mation- and stress-related pathways (interconnected
with the NF-κB, PI3K and MAPK cascades) toward the
activation of protein degradation, cell cycle and cellular
adhesion [35]. Similarly, the NLRB subfamily, namely
the NLR family apoptosis inhibitory protein (NAIP), is
an anti-apoptotic protein which acts by inhibiting (i) the
activities of multiple caspases, including caspase − 3, cas-
pase − 7 and caspase-9 [36], (ii) the autocleavage of pro-
caspase − 9 and (iii) the cleavage of procaspase − 3 by
caspase-9 [33]. Moreover, NAIP was shown to be a me-
diator of neuronal survival in several pathological condi-
tions in preventing apoptosis [37]. Various studies
showed that an increase in NAIP expression was associ-
ated with tumour growth [38, 39]. On the contrary, our
study showed the capability of ProEGCG to suppress
both anti-apoptotic molecules, NOD1 and NAIP.
On the contrary, our results showed a difference in
sensitivity between these two endometrial cancer cell
lines to ProEGCG. This might be attributed to the cells’
origin and properties. RL95–2 cells were derived from a
stage II endometrial G2 adenosquamous carcinoma. This
cell line with epithelial morphology is differentiated and
steroid responsive. On the other hand, AN3CA cells
were derived from serous type 2 endometrial carcinoma.
This cell line is poorly differentiated, steroid receptor de-
fective and tumorigenic. With the differences in hist-
ology, differentiation potential and hormone sensitivity,
this should play a pivotal role toward the sensitivity to-
ward ProEGCG in these two EC cell lines. As previously
reported, metastatic tumours (e.g. AN3 CA) are highly
resistant to cytotoxic agents. Hence, based on our re-
sults, although both cell lines showed a mitigation in
AKT activation (Fig. 4), it was more pronounced in
Rl95–2 cells than AN3 CA cells. As AKT is shown to
control cell proliferation and response to apoptosis in
multiple carcinoma, the downregulation in AKT activa-
tion would lead to greater inhibition of cell proliferation
and increased apoptotic response in Rl95–2 cells than
AN3 CA cells, as shown in Figs. 2 and 3.
Analogous to our previous report, the excised lesion
also showed that the microvessel density in the EC xeno-
graft models dwindled after ProEGCG treatment [16]. In
regard to our previous publication [16], we can deduce
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that ProEGCG may induce apoptosis in the EC cells to
prevent VEGFA secretion (in addition to preventing
VEGFA from TAMs) and thus hinder vascularization
produced by endothelial cells, and further promote EC
cell death. Interestingly, these remarkable changes were
not observed in EGCG treated cells. This clearly sug-
gested the superiority of ProEGCG (than EGCG) with
higher stability and bioavailability in reducing the
growth of the EC tumor on the xenograft. Current anti-
angiogenic drugs include VEGF inhibitor, VEGFR anti-
body and tyrosine kinase inhibitor [40]. Although some
of these have yielded promising results in treating endo-
metrial cancer, clinical trials are required to establish
their safety and efficacy. Notably, unlike these anti-
angiogenic drugs, ProEGCG did not produce any observ-
able adverse effects (e.g. weight, renal or hepatic) in the
xenograft bearing animals after receiving the treatment
This suggests that the modification of the reactive hy-
droxyl groups with peracetate groups does not induce
any toxicity. However, a longer longitudinal monitoring
is warranted.
Conclusion
In summary, we provide strong preclinical evidence of
the benefit of ProEGCG as a potential therapeutic agent
for EC. We showed that ProEGCG promoted cell death
through inhibition of the Akt and ERK signalling path-
ways and subsequently downregulated the mechanistic
pathway involved in cell proliferation and cell survival.
The therapeutic benefit of ProEGCG permitted the
shrinkage of lesion size concomitant with the attenu-
ation of new vessel formation. Our results also showed
metastatic serous cancers are not as responsive as endo-
metrioid cancers. This may indicate a difference in re-
sponse between metastatic cancer and cancer from
which it originated. Most importantly, there was no side
effect apparent in these treated animals. Moreover, our
findings clearly support ProEGCG as a potential novel
candidate for the treatment of endometrial cancer.
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Additional file 1 Supplementary Figure 1. Effects of ProEGCG and
EGCG on viability of normal human endometrial epithelial cells (HEECs).
(A) HEECs were treated with increasing doses of EGCG (20, 40, and
60 μM) and ProEGCG (20, 40, and 60 μM) for 24, 48 and 72 h. Cell viability
was assessed by MTT assay. The percentage of viable cells was calculated
as the ratio of treated cells to the control cells. Data are presented as
mean ± S.E.M. of three independent experiments. Significant differences
from the control are indicated by * (P < 0.05) and ** (P < 0.01).
Additional file 2 Supplementary Figure 2. ProEGCG suppresses
colony formation of endometrial cancer cells in 3D organoid co-culture.
Endometrial cancer cells (AN3CA: 10,000 cells. RL95–2: 20,000 cells) were
seeded onto matrigel. Cells were treated with either EGCG or ProEGCG
(A) from day 2 to day 6, or (B) from day 7 to day 11. Photographs of
spheroid sizes were taken under the microscope (100X), and the area of
spheroids was measured. Data are presented as mean ± S.E.M. of three in-
dependent experiments. Significant differences from the control are indi-
cated by * (P < 0.05) and ** (P < 0.01).
Additional file 3 Supplementary Figure 3. Immunofluorescence
staining for detection of apoptosis in human endometrial carcinoma cell
lines. (A) RL95–2 and AN3CA cells were treated with increasing doses of
EGCG (20, 40, and 60 μM), or (B) ProEGCG (20, 40, and 60 μM) for 72 h
with daily medium change and supplement. Localization and expression
of Annexin-V (green) and propidium iodide (red) were analyzed by im-
munofluorescent staining. Nuclei were counterstained using DAPI (blue).
Additional file 4 Supplementary Figure 4. Positive Control of TUNEL
staining. Mouse embryo E10 brain tissue sample was collected and
incubated with a brief treatment of DNAse 1 after permeabilization. This
was then proceeded with the TUNEL assay accordingly. Magnification
200x.
Additional file 5 Supplementary Figure 5. Full Western Blot Images
from Figs. 3 and 4. Western blot analysis of the relative protein levels of
Rl95–2 and AN3 CA cells. Quantitative analysis of the relative protein
levels of Rl95–2 and AN3 CA cells was carried out in triplicate and
repeated in 3 independent experiments. Rl95–2 and AN3 CA cells were
probed with cleaved PARP, cleaved Caspase, GAPDH antibodies.
Molecular weight (kDa) markers (MW) are shown: cleaved PARP is 116
kDa, cleaved Caspase-3 is 17/19 kDa, p-Akt is 60 kDa, Akt is 60 kDa, p-JNK
is 54/46 kDa, JNK is 54/46 kDa, p-ERK is 44/42 kDa, ERK is 44/42 kDa, p-p38
is 43 kDa, p38 is 43 kDa, and GAPDH is 37 kDa.
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